Compass Therapeutics (CMPX) Profit After Tax (2018 - 2026)
Compass Therapeutics recorded quarterly Profit After Tax of -$18.3 million in Q1 2026, down 16.55% quarter-over-quarter from -$15.7 million in Q4 2025, and down 10.12% year-over-year from -$20.4 million in Q1 2025.
Compass Therapeutics' Profit After Tax history runs 9 years deep, the most recent figure standing at -$18.3 million for Q1 2026.
- In Q1 2026, Profit After Tax fell 10.12% year-over-year to -$18.3 million; the TTM figure through Mar 2026 stood at -$68.2 million (down 23.45% YoY), while the FY2025 annual figure was -$66.5 million, down 34.66% from the prior year.
- Profit After Tax came in at -$18.3 million for Q1 2026 at Compass Therapeutics, down from -$15.7 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of -$7.2 million in Q1 2022 to a low of -$19.9 million in Q2 2025.
- A 5-year average of -$12.7 million and a median of -$12.0 million in 2022 frame the typical range for Profit After Tax.
- Across the five-year window, Profit After Tax plunged 100.42% in 2022 and increased 16.79% in 2023, its largest moves.
- Compass Therapeutics' Profit After Tax stood at -$11.6 million in 2022, then slipped by 15.71% to -$13.4 million in 2023, then declined by 12.06% to -$15.0 million in 2024, then declined by 4.54% to -$15.7 million in 2025, then decreased by 16.55% to -$18.3 million in 2026.
- According to Business Quant data, Profit After Tax over the past three periods registered -$18.3 million, -$15.7 million, and -$14.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 30.90 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Compass Therapeutics | 418.47 Mn | 223.78 Mn | - | -18.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.32 Mn |
| Dec 31, 2025 | -15.72 Mn |
| Sep 30, 2025 | -14.26 Mn |
| Jun 30, 2025 | -19.88 Mn |
| Mar 31, 2025 | -16.63 Mn |
| Dec 31, 2024 | -15.03 Mn |
| Sep 30, 2024 | -10.48 Mn |
| Jun 30, 2024 | -13.08 Mn |
| Mar 31, 2024 | -10.79 Mn |
| Dec 31, 2023 | -13.42 Mn |
| Sep 30, 2023 | -9.96 Mn |
| Jun 30, 2023 | -11.28 Mn |
| Mar 31, 2023 | -7.84 Mn |
| Dec 31, 2022 | -11.59 Mn |
| Sep 30, 2022 | -11.98 Mn |
| Jun 30, 2022 | -8.49 Mn |
| Mar 31, 2022 | -7.16 Mn |
| Dec 31, 2021 | -12.98 Mn |
| Sep 30, 2021 | -5.98 Mn |
| Mar 31, 2021 | -7.42 Mn |
| Sep 30, 2020 | -9.15 Mn |
| Jun 30, 2020 | -5.56 Mn |
| Mar 31, 2020 | -6.40 Mn |
| Dec 31, 2019 | -11,682.00 |
| Sep 30, 2019 | -8.55 Mn |
| Jun 30, 2019 | -8.81 Mn |
| Mar 31, 2019 | -10.77 Mn |
| Dec 31, 2018 | -10,142.00 |
| Sep 30, 2018 | -8,556.00 |
| Jun 30, 2018 | -8,474.00 |